Clinical Trials for Melanoma
R3767-ONC-22122
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma. View details.
Medical Oncology: 706.353.2990
Radiation Oncology: 706.548.0500
Surgical Oncology: 706.715.2430
Breast Health Program: 762.356.4780
Pharmacy: 706.353.4344
Referrals: 706.353.4346
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma. View details.

Celebrating life, survivorship, and the power of community.
Saturday June 6th
11 am – 1 pm
To RSVP and learn more, visit here